StockData

Bolt Biotherapeutics vs TuHURA Biosciences

BOLT and HURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BOLT and HURA compare

TuHURA Biosciences is the larger company, worth 8.2 times as much as Bolt Biotherapeutics ($89.2M against $10.9M).

Bolt Biotherapeutics scores higher on the StockData Score (8 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBOLTHURA
Size and price
Market cap$10.9M$89.2M
Share price$5.65$1.40
Change, 1 year23.6%−31.7%
Change, 5 years−96.9%−99.9%
Beta (5Y)0.131.98
Employees2322
StockData Score
Total score8 (better)0
Valuation score1 (better)0
Growth score1 (better)0
Performance score1 (better)0
Health score5 (better)0
Dividend score00
Valuation
P/S4.3×–
P/B1.3× (better)4.8×
FCF yield–−33.5%
Fair value$5.40–
Margin of safety−4.6%–
Growth
Revenue growth (TTM)−51.3%–
Revenue growth, 5Y average102%–
Profitability
Operating margin−1098%–
Net margin−1034%–
Return on equity−129% (better)−161%
Financial health
Debt / equity0.00–
Current ratio2.05 (better)0.18
Altman Z-score−20.86−3.21 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Buyback yield−0.28% (better)−22.6%
Shareholder yield−0.28% (better)−22.6%
Ownership
Held by institutions31.0%14.1%
Held by insiders12.2%4.9%
Insider net buying, 12 months$196K–
Short interest, % of float2.8%10.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.